# BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

> **NCT00828009** · PHASE2 · COMPLETED · sponsor: **ECOG-ACRIN Cancer Research Group** · enrollment: 70 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **BIOLOGICAL:** Tecemotide
- **DRUG:** carboplatin
- **DRUG:** cyclophosphamide
- **DRUG:** paclitaxel
- **RADIATION:** radiotherapy

## Key facts

- **NCT ID:** NCT00828009
- **Lead sponsor:** ECOG-ACRIN Cancer Research Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01-17
- **Primary completion:** 2018-08-20
- **Final completion:** 2019-05-22
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2023-07-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00828009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00828009, "BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00828009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*